HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 234-237

  Hay, C R M ^a   Ollier, W ^b   Pepper, L ^b   Cumming, A ^a   Keeney, S ^a   Goodeve, A C ^c   Colvin, B T ^d   Hill, F G H ^e   Preston, F E ^c   Peake, I R ^c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HAPLOTYPE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; INTRON; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RISK;

EID: 0031057651     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655944     Document Type: Article

References (21)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate study group. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. N Eng J Med 1993; 328: 453-9.
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Addiego J Kasper C, Abildgaard C, Hildgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with intermediate-purity VIII. Lancet 1993; 342-64.
4. Rizza CR, Spooner RGD, Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of the Haemophilia Centres of The United Kingdom. Br Med J 1983; 286: 929-34.
5. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: incidence and outcome. Br J Haematol 1990; 76: 369-71.
6. Tuddenham EGD, Cooper DN, Gitcher J et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Research 1991; 19: 4821-33.
7. Miller DS, Steinbrecher RA, Wieland K et al. The molecular genetic analysis of Haemophilia A: characteristics of six partial deletions of the factor VIII gene. Hum Genet 1990; 86: 219-27.
8. Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, et al. Factor VIII gene inversion in severe hemophilia A: results of an international consortium study. Blood 1995; 86; (6): 2206-10.
9. Frommel D, Allain JP, Saint-Paul E, Bosser C, Noel B, Mannucci PM, Pannicucci F, Blomback M, Prou-Wartelle, Muller JY. HLA antigens and factor VIII antibody in classical hemophilia. Thromb Haemost 1981; 46: 687-9.
10. Mayr WR, Lechner K, Neissner H, Papinger-Fashing I. HLADR and factor Vin antibodies in hemophilia A. Thromb Haemost 1984; 51: 293-6.
11. Alper CAA, Raum DD, Awdeh ZL, Shapiro SS, Yunis EJ. Major Histocompatibility Complex (MHC)-linked complement alleles as markers for the development of anti-factor VIII in hemophiliacs. Prog Clin Biol Res 1984; 150: 141-2.
12. Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-41.
13. Papasteriades C, Varla M, Economidou J, Mitsouli C, Louiso UK, Mandalaki T, Roumelitou A, Papevangelou G. High frequency of HLADR5 in Greek patients with hemophilia A and hemophilia B. Tissue antigens 1986; 28: 84-7.
14. Lippert LE, McFisher A, Shook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thrombosis and Haemostasis 1990; 91: 564-8.
15. Lakich D, Kazazian HH, Antonarakis SE, Gitcher J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genetics 1993; 5: 236-41.
16. Doherty DG, Vaughan RW, Donaldson PT, Mowat AP. HLA-DQA, DQB and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British Caucasoids. Hum Immunol 1991; 34: 53-7.
17. Tilikainen A, Lassus A, Karvonen J, Vartianen P, Julin M. Psoriasis and HLA-CW6. Br J Dermatol 1980; 102: 179-82.
18. Brewerton DA, Caffrey M, Hart FD, James DCO, Sturrock RD. Ankylosing spondylitis and HLA-B27. Lancet 1973; i: 904-7.
19. Donn RP, Thompson W, Pepper L, Carthy D, Farhan A, Ryder C, Southwood T, Holt L, Ollier W. Br J Rheumatol 1995; 34: 461-5.
20. Reveille JD, MacLeod MJ, Whittington K et al. Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La(SS-B) autoantibody response. J Immunol 1991; 146: 3871-6.
21. Olsen ML, Arnett FC, Reveille JD. Contrasting molecular patterns of MHC class II alleles associated with the anti-SM and anti-RNP precipitin autoantibodies in systemic lupus erythematosus. Arthritis and Rheumatism 1993; 36: 90-104.